New light shed on neuronal circuits involved in behaviour, learning and dysfunction – UNSW Newsroom

Scientists at UNSW Sydneys Decision Neuroscience Lab have made a major discovery about the way brains influence behaviour which challenges theory that has stood for 30 years.

And the findings could one day have key implications for the way we treat brain related diseases such as Parkinsons or deal with conditions like Tourettes syndrome.

In a paper published today in the prestigious journal Science, the research team of Dr Miriam Matamales and Dr Jay Bertran-Gonzalez, together with Neuroscience Lab Director, Scientia Professor Bernard Balleine, wanted to determine the relationship between the two main types of neuron found in the striatum, a major area of the brain responsible for voluntary movement in animals and humans.

They set up experiments to observe mice while they learned new actions that led to a reward of food, then examined the activity of these neurons in large areas of the striatum. They looked specifically at the activity of the two classes of neuron in this area those expressing D1 or D2 types of dopamine receptors.

For the last three decades, these D1- and D2-neurons were thought to have an independent influence on voluntary action, respectively initiating and inhibiting reward-seeking behaviour. While studying how these two types of neuron became active during learning, the team began to find an unexpectedly high degree of interaction between them which happened locally, within the striatum itself.

Lightbulb moment

For an example of behaviour where these neurons would be active, Dr Matamales suggests a simple, but common scenario of walking into a room and flicking on a light switch to find the light doesnt work.

So you walk into a room, flick the switch without even thinking about it, and theres no light, she says. You learn something has changed and so the behavioural response has to be modified by that learning. What were interested in is what changes in the brain are necessary to update that learning to realise oh, the bulbs blown, I should stop flicking the switch expecting the light to go on. Although this may seem trivial at one level, this kind of plasticity in decision making processes is going on all the time. Updating learning to control our actions is a critical aspect of brain function acquired through evolution, to stop us wasting valuable energy by repeating a task for no reward.

Professor Balleine explains that what is happening is that prior learning about behaviour tied to one outcome is put on hold while an updated version relevant to the change in the environment is rewritten.

This regulation of voluntary action is not about getting rid of or replacing the knowledge or behaviour, its about being more efficient in stopping actions that use energy for no reward, he says. Youve got a neuron, the D1-neuron, thats involved in acquiring and maintaining ongoing behaviour and another, the D2-neuron, thats engaged in updating that behaviour when there are changes in the environment. And what is game changing is that this critical interaction is going on in the striatum, not further downstream in more distant motor output structures of the brain as was thought previously.

Rethinking brain health

Professor Balleine says this new understanding of the D1 and D2 neurons intermingling in the striatum during learning could have important implications for medicine and even our concept of how voluntary actions are acquired and altered.

Our research suggests that the whole theory of basal ganglia function that people have been working with in order to try and treat diseases of various kinds, is seriously incomplete, he says.

Diseases that are associated with basal ganglia function include Parkinsons and Huntingtons disease, dementia, dystonia, Tourette syndrome and obsessive-compulsive disorder.

Dr Bertran-Gonzalez suggests that a clue to understanding at least some of these conditions could be found in the learning-related functions of the striatum.

Most basal ganglia dysfunction appears later in life and takes years to settle, he says. Some conditions are expressed by aberrant behaviour, where movements or whole actions that should be inhibited are not inhibited, perhaps because they never learned to be inhibited in the striatum, or because that learning was deficient. In such cases, in addition to simply attempting to counter uncontrolled motor movements, we should perhaps explore more progressive therapy that tries to correct this early learning. I think that we should add a learning perspective to virtually all treatments of basal ganglia dysfunction. After all, most of our current behaviour is no more than learnings work in progress.

Targeted medicine

Professor Balleine notes that with health conditions related to the basal ganglia, the striatum could be the new target area for medical intervention.

We believe these findings have the potential to re-target treatments of basal ganglia disorders to the striatum, Professor Balleine says. One of the most exciting parts of this research is that it speaks to particular connections between particular neurons within a particular structure. So it really gives great targeting information for treatment, and gives us new ways to think about these problems.

Dr Matamales says while the research raises hopes for new ways to treat health problems relating to brain function, there is still plenty of research ahead before the observations in mice are replicated in humans.

It is exciting to think that our new understanding could one day be used to target problems in the brain with more depth, she says. But the important thing you can say about this work right now is that we are providing more evidence to relate these neurons in the striatum with learning and cognition rather than simply motor output.

Hopefully this will lead to further breakthroughs that help us understand how the brain learns and how we adapt our behaviour to our environment.

See more here:
New light shed on neuronal circuits involved in behaviour, learning and dysfunction - UNSW Newsroom

Brain Organoids are Farther From Consciousness Than You Might Think – Discover Magazine

Cerebral organoids, or so-called brains in a dish, have taken the world of neuroscience by storm. These balls of neurons and brain tissue, grown in a petri dish, are supposed to mimic early brain development in humans.

Recent studies have touted swift progress, including lab-grown brains that are capable of forming neural circuits and producing brain waves similar to a developing embryo. But a new paper in Nature this week offers another take, suggesting that lab-grown brain models are far from humanlike.

In this new work, a team of scientists at the University of California, San Francisco, compared samples of real developing brains to organoids and say the lab-grown versions show patterns of abnormal development. As such, the organoids are unlikely to form the complex circuitry needed to study brain diseases.

Given these shortcomings, the odds that organoids will develop cognition or consciousness are still pretty far off, the researchers note.

Our brains rely on intricate networks of neurons to function. In real brains, neuronal cells form identities which determines their characteristics and role in the brain based on genetic instructions.

But in organoids, scientists observed that neurons appeared confused about their identities and failed to mature. This would prevent an organoid from organizing and functioning like an actual human brain, and impede the formation of specific brain circuits important for understanding diseases.

These abnormalities were not only present in the organoids created in the UCSF lab; a data analysis found them in organoid models used by other labs.

But the good news is that scientists think these abnormalities can be corrected.Signs of excess environmental stress, such as a lack of oxygen, showed up in many of the organoids' cells. Placing them in an environment resembling conditions that actual human brains encounter eased the stress and allowed the cells to develop normally.

We found that if we transplanted stressed organoid cells into the developing mouse brain, we could relieve the stress, said co-author Arnold Kriegstein, a neuroscientist at UCSF, in an email to Discover. When stress was relieved, the gene identity improved. This finding suggests that the stress induces the gene identity issues, and that both are reversible.

In light of the problems the UCSF team uncovered, Kriegstein is skeptical of some recently reported breakthroughs in organoid research and thinks the public should be, too.

There are overstated conclusions in some published papers concerning organoids, and overblown hype in the reporting about organoids, Kriegstein said. Organoids are already proving to be important models of human disease, but they are still extremely rudimentary compared to even fragments of the actual human brain. They are not brains in a dish.

View post:
Brain Organoids are Farther From Consciousness Than You Might Think - Discover Magazine

Fresh Tri Wins CDC Multi-Year Contract to Build Habit Practice into the Diabetes Prevention Program – PR Web

"This collaboration with CDCs Lifestyle Change Program has the potential to scale and impact millions of underserved people affected by prediabetes," said Kyra Bobinet, MD, MPH, CEO and Founder of Fresh Tri.

SILICON VALLEY, Calif. (PRWEB) January 30, 2020

The United States Centers for Disease Control and Prevention (CDC) has awarded Fresh Tri, a fast-growth neuroscience-based digital health company, a multi-year contract to leverage its mindset- and habit-formation technology to improve the success of the National Diabetes Prevention Program Lifestyle Change Program (LCP).

In collaboration with CDC and certain LCP partner sites, Fresh Tri will adapt its weight-loss-focused mobile app, also called Fresh Tri, and apply its neuroscience-based methodology to create a companion app for DPP LCP participants, particularly focused on better engaging underserved populations. The app will guide participants in turning the food and fitness behaviors promoted by the LCP curriculum into sustainable habits. The new version of Fresh Tri will also help LCP lifestyle coaches monitor and support LCP participants daily to further improve outcomes.

CDC selected the Fresh Tri app for adaptation based on the mobile apps demonstrated ability to help users form healthy habits. Fresh Tri does this by training users in the Iterative Mindset a practice-and-modify approach to habit change.

The scientific definition of a habit is a repeated behavior that requires no thought. In contrast, conventional goal-setting and tracking requires immense thought and can backfire by triggering the habenula, a brain area that perceives failure and then suppresses ones motivation to try again. As a result, people quit trying.

Fresh Tris research on thousands of underserved people found that adopting the Iterative Mindset enabled them to persist in their efforts and maintain motivation while they found and adjusted the right new habits to fit their lives.

Using this approach in a recent study conducted with Walmart associates, Fresh Tri demonstrated statistically-significant (p < 0.001) weight loss, habit formation, and improvements in mindset, persistence, and resilience. Fresh Tri is customizable for other healthcare organizations to target patient behavior change, as well as for employers seeking to improve various types of health habits for their employees.

This collaboration with CDCs Lifestyle Change Program has the potential to scale and impact millions of underserved people affected by prediabetes, said Kyra Bobinet, MD, MPH, CEO and Founder of Fresh Tri. We are honored by this opportunity to spread this more natural, science-based approach to sustainable behavior change and to replace the outdated model of using goals and tracking that backfires for so many people.

To request a demo, please contact Jonathan Har-Even at jhareven@freshtri.com.

###

About FreshTri Fresh Tri is a behavior-change technology company with offerings focusing on mindset, practice and iteration that invite users to test-drive healthy habits, removing the guesswork and feelings of failure that can often accompany lifestyle changes. Fresh Tri uses a simple, positive approach based on the brain science of habit formation. In a recent study, use of the Fresh Tri app, in combination with mindset training, led to statistically significant weight loss and habit formation, as well as improvements in positive psychology metrics highly associated with overall health and well-being. Find out more about Fresh Tri: freshtri.com, Instagram, Facebook

Share article on social media or email:

Excerpt from:
Fresh Tri Wins CDC Multi-Year Contract to Build Habit Practice into the Diabetes Prevention Program - PR Web

This week: Coronavirus, vaping and drugs of abuse – WRVO Public Media

China is dealing with the outbreak of a respiratory illness caused by a new coronavirus. Thousands of people have been infected; some have died. And more cases are being diagnosed in people all over the world, including a relatively small number in the United States.

Providing perspective on this outbreak is Stephen Thomas, MD, a professor of medicine and microbiology and immunology at Upstate and its chief of infectious disease.

Also on "HealthLink on Air" this week, toxicologist Christine Stork from the Upstate New York Poison Center talks about vaping dangers and the most common drugs of abuse. Tune in this Sunday, February 2 at 6 a.m. and 9 p.m. for "HealthLink on Air."

See the article here:
This week: Coronavirus, vaping and drugs of abuse - WRVO Public Media

Coronavirus outbreak in US may depend on this: ‘We just don’t know yet’ says infectious disease doc – Home – WSFX

A top infectious disease doctor warned that the likelihood of preventing a U.S. outbreak of the coronavirus dependson whether the virusis transmitted by peoplewho are not exhibiting symptoms.And that information, he warned, is something that world health experts do not know yet.

You could be carrying it and not know so you wouldnt have the symptoms. Doesnt that make it extremely dangerous? Wall Street Journal columnist Mary Anastasia OGradyasked a panel of doctors on Fox NationsDeep Dive.

The Chinese Ministry of Health has said that they believe this is possible, that people can be spreading it before they show symptoms, said Dr. Stephen Morse, who is a professor of epidemiologyat the Columbia University Medical Center.

But thats why were doing a lot of screening at the airports based largely on geography, he continued. But once it spreads further, its going to be hard to be that targeted.

I agree that we have heard that from the Chinese, but we havent seen the evidence thats behind that, saidDr. Mark Mulligan, whois a senior professor in the NYU Langone Department of Medicine anddirector of both NYU Langone Vaccine Center and theDivision of Infectious Diseases and Immunology.

We do know you can have asymptomatic infection, he went on. There are reports of people that were shown to be infected but we dont know that those people can transmit.

The World Health Organization on Thursday declared the newcoronavirus outbreaka global emergency, as38 new deaths and 1,737 new infected cases have been reported in the last 24 hours.

In general, the transmission occurs when an ill person is coughing a lot. When youre sicker, you have more virus around. It may be that older people get more illness and transmit more. Younger people, less illness, maybe transmit less. But we dont know everything yet., Dr. Mulliganwarned.

Roughly 99 percent of all cases of the virus have appeared in China but it has spread to at least 18 countries.

The American officials are all saying, Dont panic, dont panic. But you can be carrying the disease without showing the symptoms, you have all this air travel going on, its already gotten out of China. How reasonable is it to think that were not going to have a serious outbreak here? asked OGrady.

I dont think we should panic, saidDr. Janette Nesheiwat,the medical director at CityMD,an urgent care practice in New York City. But we should remain on alert and be vigilant because it can take up to two weeks for symptoms to appear.

We know that the usual sort of shoe leather, public healthsteps of isolationof cases, contact tracing, quarantining of them works, notedMulligan. So I think if those things also work for this novel coronavirus, that we do have the opportunity to contain it.

However, Mulligan cautioned if it is shown that individuals can carry and transmit the virus without exhibiting symptoms that would be a troubling discovery.

We think that we have a real opportunity [to contain coronavirus], assuming there arent any curves like this thing about asymptomatic individuals transmitting. If that were true, that would change things, he concluded.

To see all ofDeep Divego toFox Nationand join today.

CLICK HERE TO SIGN UP FOR A FOX NATION FREE TRIAL

Fox Nationprograms are viewable on-demand and from your mobile device app, but only for Fox Nation subscribers.Go to Fox Nationto start a free trial and watch the extensive library from Tomi Lahren, Pete Hegseth, Abby Hornacek, Laura Ingraham, Ainsley Earhardt, Greg Gutfeld, Judge Andrew Napolitano and many more of your favorite Fox News personalities.

Fox News Vandana Rambaran contributed to this report.

Continue reading here:
Coronavirus outbreak in US may depend on this: 'We just don't know yet' says infectious disease doc - Home - WSFX

Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in…

WATERTOWN, Mass., Jan. 30, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity as the first dedicated microbiome CDMO.

As Chief Operations Officer, Dave will be responsible for driving the continued growth of Arranta's operations, including the ongoing expansion of the company's Microbiome process development center of excellence in Gainesville, FL as well as operationalizing Arranta's new best-in-class GMP facility in Watertown, MA. He is an accomplished business leader with a demonstrated track record of success within the contract development and manufacturing services industry.

Dave brings over 20 years of broad operational and commercial experience in the CRO and CDMO sectors. Most recently, Dave served as the Senior Vice President & Head of AMRI's Drug Product business unit where he had responsibility for sales and operations. During his tenure, he led the division through a period of significant growth and capacity expansion. Prior to that, Dave held roles of increasing responsibility at Aptuit and Charles River Laboratories in the UK, Italy and USA. Dave holds an MBA in strategy, finance and marketing from the University of Edinburgh and an undergraduate degree in Business.

Jason Rahal has over 25 years of experience in biotechnology. Prior to joining Arranta as SVP of Business Development, Jason was a member of the senior management team at Cobra Biologics, a CDMO providing ATMP services including Live Biotherapeutic Products (LBPs) with facilities in the United Kingdom and Sweden. Jason initially joined Cobra as VP Business Development in 2002, as the first US based employee to establish the company's presence in North America, he was promoted to SVP Business Development in 2006.

Prior to Cobra, Jason worked at Excell Biotech, a biologics CDMO based in Edinburgh, Scotland and Stratagene Cloning Systems based in La Jolla, CA in various business development and sales positions. Jason has a strong background in molecular and cell biology, beginning his career at Northwestern University in Evanston, IL managing a molecular endocrinology laboratory with several peer reviewed publications. Jason holds a BA in Biology and Studio Art from Knox College.

"I am delighted to have two experienced leaders join Arranta Bio's senior team as we continue to build out our organization and invest in facilities as the leading end-to-end dedicated CDMO supporting microbiome pioneers with our services" said Mark Bamforth, President & CEO of Arranta.

Almost 200 companies are actively exploring the linkage between diseases and the microbiome millions of bacteria, fungi, protozoa and viruses that live inside and on the human body in order to identify therapeutic targets. Scientists have called it the second genome, and in fact, the number of genes in the microbes making up one person's microbiome is estimated to be at least 200 times the number in the human genome.

Over the last decade, there has been rapid acceleration in scientific understanding of the composition and functions of the gut microbiota. Arranta is proud to be the leading CDMO focused on supporting the supply needs of these innovators.

About Arranta BioFounded in 2019, Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. Arranta Bio acquired CaptozymeTM the leader in process development and clinical contract manufacturing for microbiome pioneers whose experienced team has worked with and developed processes for over 125 different species spanning 80 different genera of live biotherapeutics since 2009. Headed by a management team and technical experts with a proven track record in both process development and contract manufacturing through fermentation to lyophilization and encapsulation of live biopharmaceuticals, Arranta offers the knowledge and resources necessary to help clients develop and manufacture promising new microbiome therapies to meet the needs of patients. Additional information about Arranta is available at http://www.arrantabio.com. Enquiries can be sent to info@arrantabio.com

About Ampersand Capital PartnersFounded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at http://www.ampersandcapital.com

Arranta Bio Media contact: Guy TieneThat's Nice LLCT: +1 212 366 4455E: guy@thatsnice.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/arranta-bio-announces-key-leadership-additions-of-chief-operations-officer-and-svp-of-business-development-as-it-commits-to-a-100m-investment-in-building-end-to-end-microbiome-capacity-300995736.html

SOURCE Arranta Bio

Read more:
Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in...

Cancer cure: Collaboration between Ervaxx and Cardiff University to develop T-cell immunotherapy treatment – EconoTimes

The coronavirus has everyone on high alert, but scientists have not forgotten about the existing diseases that have yet to have a cure, such as cancer. A new partnership between Cardiff University and biotechnology company Ervaxx was announced in order to develop the T-cell immunotherapy treatment further.

As announced on the Ervaxx site, the two institutions will collaborate in the development of a potential cure in the form of utilizing Dark Antigens to which the company is known for, in order to develop T-cell receptor-based immunotherapy treatments for cancer. Ervaxx will be funding the program. The partnership between the two groups will help bring forward the findings Professor Andrew Sewell and his team have documented.

They were able to identify a T-cell clone that can target and kill many types of cancer cells while keeping the healthy cells intact. This T-cell clone targets an MHC class-1-related protein named MR1, which is a cancer-specific ligand. This breakthrough may provide a universal cancer cure and change the game into the concept of immunotherapy as a treatment for the disease.

As part of the collaboration, Ervaxx will have exclusive access to the patents at Cardiff University that claim T-cells and T-cell receptors reacting to cancer-specific antigens. On the universitys side, Professor Sewell said, This collaboration will use our world-class expertise in T-cell biology to identify T-cells and TCRs reactive to those targets and pave the way for a new wave of treatments in cancer and potentially other areas,

Although this type of treatment for cancer has already been discovered years back, what makes this significant is that this method is slowly becoming accessible to more parts of the world. As pharmaceutical giants, while they may offer this type of treatment, the accessibility is very limited. Therapies like TCR-T and CAR-T, which also make use of a patients T-cells, which are genetically modified to kill the cancerous cells and re-introduced into the body are already existing. However, the disadvantage of these treatments is that it targets certain types of blood cancer and has not been successful when it comes to tumors.

Professor Sewell stated regarding their discovery, Not only would the treatment work for most types of cancer, but the same approach could be applied in all patients.

Read the original:
Cancer cure: Collaboration between Ervaxx and Cardiff University to develop T-cell immunotherapy treatment - EconoTimes

Aparna Bhaduri – The Conversation US

Profile Articles Activity

Aparna Bhaduri earned a B.S in Biochemistry and Cell Biology and a B.A in Political Science from Rice University in 2010. She completed her doctoral studies at Stanford University in Cancer Biology in 2016, where she focused on epithelial tissue differentiation and neoplasms She is currently a postdoctoral scholar at the University of California San Francisco in the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, in the lab of Dr. Arnold Kriegstein. As a postdoctoral scholar, she has used single-cell RNA sequencing to characterize cell types in the developing cortex across cortical areas, in human and non-human primates, and in glioblastoma. Because experimental manipulations of the developing human cortex will require in vitro models, she has been using similar approaches to compare cells types in organoid models and primary tissues. Her long term interests are in understanding how stem cells during cortical development give rise to the human brain, and how aspects of these developmental programs can be hijacked in cancers such as glioblastoma. In order to explore these questions, Aparna uses single-cell genomics, informatic analysis, and organoid models.

See original here:
Aparna Bhaduri - The Conversation US

Talented Teacher – HSC Newsbeat

Angela Wandinger-Ness, PhD, professor in The University of New Mexico Department of Pathology, is being honored by the American Association for the Advancement of Science (AAAS) with its 2020 Lifetime Mentor Award.

She will receive the award, which recognizes her for mentoring some 270 scientists over her 29-year teaching career, at the associations annual meeting in Seattle on February 15.

Wandinger-Ness is both the associate director for education, training and mentoring and the Victor and Ruby Hansen Surface Endowed Professor in Cancer Cell Biology and Clinical Translation at the UNM Comprehensive Cancer Center.

I am deeply humbled by being nominated and receiving this award, she said, adding that she is especially moved to know that she was nominated for the award by people she trained and mentored who are now respected scientists in their own right.

Dr. Wandinger-Ness was an incredible mentor to me, providing personal and professional guidance throughout my time in her laboratory and beyond, wrote Mary-Pat Stein, professor of biology at California State University, Northridge, in a nominating letter to the AAAS.

The AAAS Mentor Award honors individuals who during their careers demonstrate extraordinary leadership to increase the participation of underrepresented groups in science and engineering fields and careers. These groups include women of all racial or ethnic groups African American, Native American and Hispanic men and people with disabilities.

Wandinger-Ness has twice been singled out by her colleagues at UNM for the annual Excellence in Research Award. In nominating her for the Teaching and Learning category in 2019, Cancer Center CEO Cheryl Willman, MD, hailed her unwavering commitment to scholarship in teaching and mentoring trainees at all levels of learning.

Willman added, Dr. Wandinger-Ness is a devoted and compassionate research mentor who invests her time to nurture and develop a more diverse scientific community and scientific leaders for our future.

Wandinger-Ness was elected a fellow of the AAAS in 2012. Her research has focused on GTPases, a family of enzymes that operate as molecular switches in many different cellular functions. She currently is looking for way to translate her work into potential therapies for ovarian cancer.

Wandinger-Ness joined the UNM faculty in 1998 after seven years at Northwestern University. Through the years, she mentored dozens of minority trainees, including 15 bachelors and masters students who went on to earn doctorate degrees, 26 PhD students and 53 postdoctoral fellows.

She was recruited to UNM by Mary Lipscomb, MD, then-chair of the Department of Pathology. She was an absolute 200% advocate for me, Wandinger-Ness says. She thought I walked on water, which I knew I didnt . . . that was the first time I felt that I understood what it meant to have somebody who gets you.

Wandinger-Ness, whose parents emigrated to the U.S. following World War II, recalls growing up feeling the animosity many people still held toward Germans.

I was assimilated, she says. Thats not true for a lot of people who come as immigrants. For me, it is deeply personal to train diverse trainees of every stripe to see that they should be welcome and part of this diverse community.

Excerpt from:
Talented Teacher - HSC Newsbeat